Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 perioperative dostarlimab versus standard treatment in resectable dMMR/MSI-H colon cancer
CTR20244229Phase 3Active
- Sponsor
- GSK
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dostarlimab in colon adenocarcinoma, colorectal cancer (CRC), sponsored by GSK. Started Dec 2024; status: active.
02
Drugs
dostarlimab
03
Conditions
colon adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20244229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244229.